Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.

Grade Last Price % Change Price Change
D 2.8 -1.58% -0.05
CKPT closed down 1.58 percent on Monday, April 19, 2021, on 37 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical CKPT trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Inside Day Range Contraction -5.72%
Up 3 Days in a Row Strength -5.72%
Oversold Stochastic Weakness -4.44%
200 DMA Support Bullish -2.44%
Hammer Candlestick Bullish -2.44%
Stochastic Buy Signal Bullish -2.44%
Lizard Bullish Bullish Day Trade Setup -2.44%
Doji - Bullish? Reversal -2.44%
Lower Bollinger Band Walk Weakness -2.44%
Older End-of-Day Signals for CKPT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
200 DMA Support about 20 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Down 3% about 21 hours ago
Down 2 % about 21 hours ago
Fell Below 200 DMA about 21 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Checkpoint Therapeutics, Inc. Description

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Adp Epidermal Growth Factor Receptor Checkpoint Inhibitor Immune Checkpoint Solid Tumor Cancers Tumor Necrosis Factor Necrosis Immuno Oncology Biopharmaceutical Tumor Necrosis

Is CKPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.3762
52 Week Low 1.44
Average Volume 1,478,706
200-Day Moving Average 2.77
50-Day Moving Average 3.33
20-Day Moving Average 3.06
10-Day Moving Average 2.92
Average True Range 0.21
ADX 20.23
+DI 15.36
-DI 25.61
Chandelier Exit (Long, 3 ATRs ) 3.02
Chandelier Exit (Short, 3 ATRs ) 3.35
Upper Bollinger Band 3.43
Lower Bollinger Band 2.69
Percent B (%b) 0.15
BandWidth 24.44
MACD Line -0.13
MACD Signal Line -0.11
MACD Histogram -0.0158
Fundamentals Value
Market Cap 170.47 Million
Num Shares 60.9 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -2.77
Price-to-Sales 115.27
Price-to-Book 4.59
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.03
Resistance 3 (R3) 3.03 2.97 2.99
Resistance 2 (R2) 2.97 2.91 2.96 2.97
Resistance 1 (R1) 2.88 2.87 2.85 2.88 2.96
Pivot Point 2.82 2.82 2.80 2.81 2.82
Support 1 (S1) 2.73 2.76 2.70 2.73 2.64
Support 2 (S2) 2.67 2.72 2.66 2.63
Support 3 (S3) 2.58 2.67 2.61
Support 4 (S4) 2.58